It is now clearly recognized that SLE patients are at high risk of developing CVD, and this excessive risk is especially pronounced in premenopausal women. Increased ADMA in turn contributes directly to oxidative stress by causing endothelial NOS uncoupling and switching it to a superoxide synthase. Besides NADPH oxidase, uncoupling eNOS has been identified as an important source of ROS and its expression was significantly increased at both messenger RNA (mRNA) and protein levels in AIA rats. This eNOS uncoupling contributes to increased ROS production and decreased nitric oxide formation and consequent endothelial dysfunction . In this study, we investigated the effects of STA on the Hcy-induced endothelial dysfunction and with the emphasis on its role in eNOS uncoupling and the underlying mechanism. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart. Endothelial dysfunction is one of the main age-related arterial phenotypes responsible for cardiovascular disease (CVD) in older adults. B. Imboden, P. Y. Hsue, and P. Ganz, “Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis,”, R. Agca, S. C. Heslinga, S. Rollefstad et al., “EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update,”, M. J. L. Peters, D. P. M. Symmons, D. McCarey et al., “EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis,”, M. F. Piepoli, A. W. Hoes, S. Agewall et al., “2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR),”, JBS3 Board, “Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3),”, C. M. Quiñonez-Flores, S. A. González-Chávez, D. Del Río Nájera, and C. Pacheco-Tena, “Oxidative stress relevance in the pathogenesis of the rheumatoid arthritis: a systematic review,”, A. J. Kattoor, N. V. K. Pothineni, D. Palagiri, and J. L. Mehta, “Oxidative stress in atherosclerosis,”, X. Yang, Y. Li, Y. Li et al., “Oxidative stress-mediated atherosclerosis: mechanisms and therapies,”, K. H. Park and W. J. Till now, there are no biomarkers that predict CV events in SLE patients, and the known ones used to assess CV risk in the general population have limited or no value in SLE [143–145]. Kato M, Roberts-Thomson P, Phillips BG, Haynes WG, Winnicki M, Accurso V, Somers VK. The latter notion has been supported by findings in atherosclerosis and other cardiovascular disorders where arginase expression or activity has been found increased, suggesting that it plays a predominant role in these conditions [124–127]. In diabetic and obesity/insulin resistance states, the endothelial dysfunction is incremented promoting the development and progression of vascular diseases [].Endothelial dysfunction … ( 145 ) confirmed the improvement … Elevated superoxide levels are also the result of peroxynitrite action-induced protein phosphatase 2A (PP2A) activation, which leads in turn to the dephosphorylation of eNOS and therefore decrease in enzyme activity and subsequent NO generation [31, 32]. Over the last decades, it has become clear that the vascular endothelium plays the central role throughout the atherosclerotic disease process, and all alterations initiating the onset and promoting the progression of the disease depend on the dynamic changes in endothelial cell phenotype. Indeed, it has been demonstrated in vitro that in the presence of anti-dsDNA, methylation of arginine residues in proteins by PRMT I is increased; therefore, anti-dsDNA antibodies may be a trigger for enhanced ADMA production in SLE [160]. Balance between production and degradation of nitric oxide (NO) by oxidative stress determines endothelial NO bioavailability. The uncoupling transformation of endothelial nitric oxide synthase (eNOS), which turns the enzyme into a superoxide generator, contributes to diabetic endothelial dysfunction in T1DM (4, 5). The latter can be also due to increased endothelial cell turnover with potential liberation of ADMA during cell catabolism. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. eNOS dysfunction was reversible with the addition of BH4. A. Vita and J. F. Keaney Jr., “Endothelial function: a barometer for cardiovascular risk?”, J. P. Halcox, A. E. Donald, E. Ellins et al., “Endothelial function predicts progression of carotid intima-media thickness,”, H. Brunner, J. R. Cockcroft, J. Deanfield et al., “Endothelial function and dysfunction. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Biondi R, Ambrosio G, De Pascali F, Tritto I, Capodicasa E, Druhan LJ, Hemann C, Zweier JL. Peroxynitrite oxidizes tetrahydrobiopterin (BH4), the eNOS cofactor to the trihydrobiopterin (BH3) radical, resulting in the eNOS uncoupling, perpetual superoxide production, and subsequent peroxynitrite formation [27]. Protein expressions of P‐eNOS‐Ser‐1177 and total eNOS were unaffected by hypercholesterolemia. The uncoupled enzyme generates superoxide rather than NO leading to further limitation of BH4 availability. It is thought that among these two enzymes, DHFR is critical to eNOS function, especially in cells that do not contain the apparatus required for efficient synthesis of BH4 or under conditions of low total biopterin levels, as recycling it can reduce eNOS-dependent oxidation of BH4 that would further decrease BH4 levels and enhance eNOS uncoupling [82]. Due to the complexity of the processes observed in RA and atherosclerosis, contributions of traditional and disease-related risk factors cannot be excluded as well as other mechanisms of DMARD action compared with increased NOS activity/expression. Schreiber F, Beutler M, Enning D, Lamprecht-Grandio M, Zafra O, Gonzalez-Pastor JE, de Beer D. The role of nitric-oxide-synthase-derived nitric oxide in multicellular traits of Bacillus subtilis 3610: biofilm formation, swarming, and dispersal. A decrease in BH4 levels in RA patients was attributed by the authors to increased expression and activation of inducible nitric oxide synthase (iNOS) in endothelial cells during chronic inflammation, which leads to eNOS uncoupling via limiting BH4 availability for eNOS. Activated NAD(P)H oxidase in the penis is an initial source of oxidative stress resulting in eNOS uncoupling, thus providing a mechanism of eNOS uncoupling and endothelial dysfunction … Jelic S, Le Jemtel TH. To date, no studies were conducted to determine direct effects of IFN on eNOS function and NO generation. BH2 binds with fairly high affinity to eNOS without supporting its catalytic activity [75]. Several drugs currently in clinical use, inhibitors of the renin-angiotensin-aldosterone system, statins, and nebivolol, show many pleiotropic actions. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Chronic systemic inflammation is considered an independent CV risk factor, and it contributes significantly to oxidative stress. Peroxynitrite directly oxidizes the reduced glutathione (GSH), its endogenous scavenger, which plays a major role in the cellular defense against reactive oxygen species. Tetrahydrobiopterin binding kinetics, specificity, and allosteric interaction with the substrate domain,”, M. Ishii, S. Shimizu, T. Nagai, K. Shiota, Y. Kiuchi, and T. Yamamoto, “Stimulation of tetrahydrobiopterin synthesis induced by insulin: possible involvement of phosphatidylinositol 3-kinase,”, A. L. Moens and D. A. Kass, “Tetrahydrobiopterin and cardiovascular disease,”, K. Chalupsky and H. Cai, “Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase,”, M. J. Crabtree, A. Although there is extensive evidence … Data from studies determining the impact of short-term anti-TNF administration are also inconsistent. The studies investigating a possible impact of the disease-modifying antirheumatic drugs (DMARDs) on ADMA levels also provided conflicting results. In contrast, eNOS activity was found decreased with no change in its expression, and the authors attributed this discrepancy between eNOS activity and expression to decreased availability of the substrate for the enzyme. Prediction of coronary heart disease using risk factor categories. Impact on nitric oxide-mediated formation of cyclic GMP,”, W. Shi, C. J. Meininger, T. E. Haynes, K. Hatakeyama, and G. Wu, “Regulation of tetrahydrobiopterin synthesis and bioavailability in endothelial cells,”, M. J. Crabtree and K. M. Channon, “Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease,”, U. Landmesser, S. Dikalov, S. R. Price et al., “Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension,”, U. Förstermann, N. Xia, and H. Li, “Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis,”, M. J. Crabtree, C. L. Smith, G. Lam, M. S. Goligorsky, and S. S. Gross, “Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS,”, M. J. Crabtree, A. L. Tatham, A. Copyright © 2020 Anna Łuczak et al. The observed effects of the glycolysis … Endothelial nitric oxide synthase (eNOS) uncoupling is a mechanism that leads to endothelial dysfunction. Lim MH, Xu D, Lippard SJ. Another part of this review article will address pharmaceutical interventions preventing or reversing eNOS uncoupling and thereby normalize vascular function in a given disease setting. ADMA also significantly increases TNF-α levels in human endothelial cells and thus participates in the pathogenesis of vascular injury in RA [56, 62, 66, 67, 69]. The best-studied mechanisms thus far are the depletion of eNOS cofactor BH4, L-arginine deficiency, and increase in endogenous eNOS inhibitor, ADMA. Anna Łuczak, Marta Madej, Agata Kasprzyk, Adrian Doroszko, "Role of the eNOS Uncoupling and the Nitric Oxide Metabolic Pathway in the Pathogenesis of Autoimmune Rheumatic Diseases", Oxidative Medicine and Cellular Longevity, vol. Activated NAD(P)H oxidase in the penis is an initial source of oxidative stress resulting in eNOS uncoupling, thus providing a mechanism of eNOS uncoupling and endothelial dysfunction … BH4 and high concentrations of BH2 inhibit GTPCH-1 and subsequently de novo synthesis of BH4, while insulin and mediators such as interferon gamma (IFN-γ), TNF-α, and interleukin-1 beta (IL-1β) can upregulate its activity and expression [77–80]. We demonstrated that STA effectively reversed the Hcy-induced endothelial dysfunction and prevented eNOS uncoupling … Indeed, numerous studies have confirmed its role as an established independent predictor for cardiovascular events and all-cause cardiovascular mortality [43–45]. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. The uncoupling of the VEGF–NO ∙ axis in the glomeruli resulting from eNOS inactivation has been reported in glomerular endothelial dysfunction (182). We postulate a role of eNOS uncoupling for reduced number and function of EPC in diabetes. Molecular Mechanism of eNOS Uncoupling. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Another part of this review article will address pharmaceutical interventions preventing or reversing eNOS uncoupling and thereby normalize vascular function in a given disease setting. A depletion of eNOS cofactor tetrahydrobiopterin (BH 4), an L-arginine deficiency, and an increase in endogenous eNOS inhibitor, asymmetric dimethylarginine (ADMA), leads to eNOS uncoupling.Produced by the uncoupled enzyme, superoxide scavenges nitric oxide (NO) leading to the peroxynitrite formation. Fox, and N. Kashihara, “Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis,”, K. M. Mäki-Petäjä, L. Day, J. Cheriyan et al., “Tetrahydrobiopterin supplementation improves endothelial function but does not alter aortic stiffness in patients with rheumatoid arthritis,”, K. M. Mäki-Petäjä, J. Cheriyan, A. D. Booth et al., “Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction,”, Y. Rikitake and J. K. Liao, “Rho GTPases, statins, and nitric oxide,”, P. Totoson, K. Maguin-Gaté, A. Prigent-Tessier et al., “Etanercept improves endothelial function via pleiotropic effects in rat adjuvant-induced arthritis,”, C. F. Spurlock III, H. M. Gass IV, C. J. Bryant, B. C. Wells, N. J. Olsen, and T. M. Aune, “Methotrexate-mediated inhibition of nuclear factor, W. Chen, L. Li, T. Brod et al., “Role of increased guanosine triphosphate cyclohydrolase-1 expression and tetrahydrobiopterin levels upon T cell activation,”, D. Popov, G. Costache, A. Georgescu, and M. Enache, “Beneficial effects of L-arginine supplementation in experimental hyperlipemia-hyperglycemia in the hamster,”, N. Pahlavani, M. Jafari, M. Rezaei et al., “L-Arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial,”, J. P. Lekakis, S. Papathanassiou, T. G. Papaioannou et al., “Oral L-arginine improves endothelial dysfunction in patients with essential hypertension,”, A. Chauhan, R. S. More, P. A. Mullins, G. Taylor, M. C. Petch, and P. M. Schofield, “Aging-associated endothelial dysfunction in humans is reversed by L-arginine,”, J. Y. Dong, L. Q. Qin, Z. Zhang et al., “Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials,”, P. Clarkson, M. R. Adams, A. J. Powe et al., “Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults,”, H. Drexler, A. M. Zeiher, K. Meinzer, and H. Just, “Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine,”, R. H. Boger, S. M. Bode-Boger, A. Mugge et al., “Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production,”, G. Siasos, D. Tousoulis, C. Vlachopoulos et al., “The impact of oral L-arginine supplementation on acute smoking-induced endothelial injury and arterial performance,”, Y. Xiong, M. F. Fru, Y. Yu, J. P. Montani, X. F. Ming, and Z. Yang, “Long term exposure to L-arginine accelerates endothelial cell senescence through arginase-II and S6K1 signaling,”, J. Rodrigues-Krause, M. Krause, I. M. G. D. Rocha, D. Umpierre, and A. P. T. Fayh, “Association of l-arginine supplementation with markers of endothelial function in patients with cardiovascular or metabolic disorders: a systematic review and meta-analysis,”, H. A. Walker, E. McGing, I. Fisher et al., “Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance,”, T. S. Alvares, C. A. Conte-Junior, J. T. Silva, and V. M. F. Paschoalin, “L-Arginine does not improve biochemical and hormonal response in trained runners after 4 weeks of supplementation,”, Z. Bahadoran, P. Mirmiran, Z. Tahmasebinejad, and F. Azizi, “Dietary L-arginine intake and the incidence of coronary heart disease: Tehran lipid and glucose study,”, T. Sun, W. B. Zhou, X. P. Luo, Y. L. Tang, and H. M. Shi, “Oral L-arginine supplementation in acute myocardial infarction therapy: a meta-analysis of randomized controlled trials,”, T. S. Alvares, C. A. Conte-Junior, J. T. Silva, and V. M. Paschoalin, “Acute L-arginine supplementation does not increase nitric oxide production in healthy subjects,”, J. Loscalzo, “Adverse effects of Supplementall-Arginine in Atherosclerosis,”, Y. C. Luiking, G. A. M. ten Have, R. R. Wolfe, and N. E. P. Deutz, “Arginine de novo and nitric oxide production in disease states,”, G. Wu, F. W. Bazer, T. A. Davis et al., “Arginine metabolism and nutrition in growth, health and disease,”, R. B. Caldwell, H. A. Toque, S. P. Narayanan, and R. W. Caldwell, “Arginase: an old enzyme with new tricks,”, J. Pernow and C. Jung, “The emerging role of arginase in endothelial dysfunction in diabetes,”, R. Lucas, D. Fulton, R. W. Caldwell, and M. J. Romero, “Arginase in the vascular endothelium: friend or foe?”, F. K. Johnson, K. J. Peyton, X. M. Liu et al., “Arginase promotes endothelial dysfunction and hypertension in obese rats,”, J. Pernow and C. Jung, “Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?”, L. A. Rabelo, F. O. Ferreira, V. Nunes-Souza, L. J. S. Fonseca, and M. O. F. Goulart, “Arginase as a critical prooxidant mediator in the binomial endothelial dysfunction-atherosclerosis,”, W. S. Shin, D. E. Berkowitz, and S. W. Ryoo, “Increased arginase II activity contributes to endothelial dysfunction through endothelial nitric oxide synthase uncoupling in aged mice,”, S. Chandra, M. J. Romero, A. Shatanawi, A. M. Alkilany, R. B. Caldwell, and R. W. Caldwell, “Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway,”, S. Sankaralingam, H. Xu, and S. T. Davidge, “Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia,”, J. Suwanpradid, M. Rojas, M. A. Behzadian, R. W. Caldwell, and R. B. Caldwell, “Arginase 2 deficiency prevents oxidative stress and limits hyperoxia-induced retinal vascular degeneration,”, K. K. McDonald, S. Zharikov, E. R. Block, and M. S. Kilberg, “A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the arginine paradox,”, K. J. Peyton, D. Ensenat, M. A. Azam et al., “Arginase promotes neointima formation in rat injured carotid arteries,”, W. Durante, F. K. Johnson, and R. A. Johnson, “Arginase: a critical regulator of nitric oxide synthesis and vascular function,”, H. Li and U. Forstermann, “Pharmacological prevention of eNOS uncoupling,”, C. Zhu, Y. Yu, J. P. Montani, X. F. Ming, and Z. Yang, “Arginase-I enhances vascular endothelial inflammation and senescence through eNOS-uncoupling,”, C. Prati, A. Berthelot, D. Wendling, and C. Demougeot, “Endothelial dysfunction in rat adjuvant-induced arthritis: up-regulation of the vascular arginase pathway,”, C. Prati, A. Berthelot, B. Kantelip, D. Wendling, and C. Demougeot, “Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis,”, L. A. Holowatz, L. Santhanam, A. Webb, D. E. Berkowitz, and W. L. Kenney, “Oral atorvastatin therapy restores cutaneous microvascular function by decreasing arginase activity in hypercholesterolaemic humans,”, F. Verhoeven, P. Totoson, C. Marie et al., “Diclofenac but not celecoxib improves endothelial function in rheumatoid arthritis: a study in adjuvant-induced arthritis,”, M. McMahon, B. H. Hahn, and B. J. Skaggs, “Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention,”, V. Teixeira and L. S. Tam, “Novel insights in systemic lupus erythematosus and atherosclerosis,”, L. B. Lewandowski and M. J. Kaplan, “Update on cardiovascular disease in lupus,”, M. J. Roman, B. Endothelial dysfunction (ED), the early feature of atherosclerosis, precedes the development of morphologic changes and is the earliest detectable impairment of vascular function [4, 5]. The current European guidelines on cardiovascular disease (CVD) prevention in clinical practice recommend to use a 1,5-factor multiplier for CV risk in rheumatoid arthritis as well as in other autoimmune inflammatory diseases. Moreover, STA prevented decreases of GTPCH1 and DHFR levels in Hcy-treated BAECs. Peng YJ, Overholt JL, Kline D, Kumar GK, Prabhakar NR. Hurshman AR, Krebs C, Edmondson DE, Huynh BH, Marletta MA. 2020, Article ID 1417981, 15 pages, 2020. https://doi.org/10.1155/2020/1417981, 1Department of Rheumatology, Wroclaw Medical University, Poland, 2Department of Internal Medicine, Hypertension and Clinical Oncology, Wroclaw Medical University, Poland. Abstract Endothelial dysfunction is one of the main age‐related arterial phenotypes responsible for cardiovascular disease (CVD) in older adults. Similarly, promoting abnormal remodeling and neointimal hyperplasia reduced NO bioavailability [134, 135]. In conclusion, our data demonstrate for the first time that activation of p47 phox and NOXO1-dependent NOX1 mediates eNOS uncoupling and endothelial dysfunction … KEYWORDS anthocyanins, eNOS … All these mechanisms are discussed below. Wang P, Zweier JL. Therefore, they indicated that increase in BH4 availability due to decreased ROS production achieved with fluvastatin therapy prevents eNOS uncoupling [97, 100]. Formation of a pterin radical in the reaction of the heme domain of inducible nitric oxide synthase with oxygen. It also reduces endothelial transport of L-arginine, the exclusive substrate for eNOS, and increases the rate of L-arginine efflux [28]. Similarly, there is scarcity of data on the interactions between the NO metabolic pathway and disease-related factors. This eNOS uncoupling contributes to increased ROS production and decreased nitric oxide formation and consequent endothelial dysfunction . Endothelial dysfunction occurs already in pre-diabetic stages of insulin resistance and subsequently contributes to smooth muscle cell proliferation and platelet and leukocyte adhesion as well as atherogenesis. Cunnington C, Van Assche T, Shirodaria C, Kylintireas I, Lindsay AC, Lee JM, Antoniades C, Margaritis M, Lee R, Cerrato R, Crabtree MJ, Francis JM, Sayeed R, Ratnatunga C, Pillai R, Choudhury RP, Neubauer S, Channon KM. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. It is thought that the destructive loop of oxidative stress and inflammation leads to development of endothelial dysfunction, a fundamental feature of atherosclerosis [23]. Induction of sensory long-term facilitation in the carotid body by intermittent hypoxia: implications for recurrent apneas. However, limited evidence is available for primary SS regarding premature atherosclerosis and endothelial dysfunction. However, a study conducted in patients with high-risk melanoma showed that therapy with pegylated IFN-α results in a marked decrease in the synthesis of NO and arginine availability [154, 155]. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Also, ROS generated by myeloperoxidase released from activated neutrophils contribute to decreased BH4 levels via their oxidation to inactive BH2 [98, 99]. However, to date, there are no systemic analyses on the role of eNOS uncoupling in the excess CV mortality linked with autoimmune rheumatic diseases. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr, Lerman A. GTPCH I is a rate-limiting enzyme for BH4 biosynthesis and therefore plays a major role in controlling the NOS function [71, 72]. Formation of a protonated trihydrobiopterin radical cation in the first reaction cycle of neuronal and endothelial nitric oxide synthase detected by electron paramagnetic resonance spectroscopy. Although the relationship between systemic inflammation in RA and arginase activity warrants further research, authors avail this disconnection between arginase activity and RA disease activity for the clinical practice and proposed arginase activity as a potential biomarker of increased CVD risk independent of the patient’s disease state [55]. Prospective study of the association between sleep-disordered breathing and hypertension. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Pressure overload induced by transverse aortic constriction was associated with eNOS uncoupling … Therefore, ED is regarded as a common mechanism for various CV disorders, and numerous clinical studies have shown that endothelial dysfunction can be an independent predictor of future cardiovascular disease (CVD) progression and acute thrombotic events [8–11]. Glucose concentrations and A1C values were determined in the morning after an overnight fasting period. B. Hale, and K. M. Channon, “Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency,”, G. L. Pierce and T. J. Larocca, “Reduced vascular tetrahydrobiopterin (BH4) and endothelial function with ageing: is it time for a chronic BH4 supplementation trial in middle-aged and older adults?”, D. M. McDonald, K. S. Edgar, T. A. Gardiner, and Z. S. Katusic, “BH4 supplementation improves vascular integrity during hyperoxia in oxygen induced retinopathy,”, S. Ueda, H. Matsuoka, H. Miyazaki, M. Usui, S. Okuda, and T. Imaizumi, “Tetrahydrobiopterin restores endothelial function in long-term smokers,”, E. Stroes, J. Kastelein, F. Cosentino et al., “Tetrahydrobiopterin restores endothelial function in hypercholesterolemia,”, T. Heitzer, K. Krohn, S. Albers, and T. Meinertz, “Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus,”, T. Heitzer, C. Brockhoff, B. Mayer et al., “Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : evidence for a dysfunctional nitric oxide synthase,”, Q. Wang, M. Yang, H. Xu, and J. Yu, “Tetrahydrobiopterin improves endothelial function in cardiovascular disease: a systematic review,”, D. Hurlimann, G. Noll, C. D. Gatti et al., “Oral treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolemia,”, T. Nyström, A. Nygren, and A. Sjöholm, “Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease,”, K. L. Moreau, A. Meditz, K. D. Deane, and W. M. Kohrt, “Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women,”, Y. Higashi, S. Sasaki, K. Nakagawa et al., “Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals,”, B. Peroxynitrite inactivates prostacyclin synthase (PGIS), an enzyme that catalyzes the isomerization of prostaglandin H2 to prostacyclin, widely known for its vasoprotective activity, therefore resulting in formation of vasoconstricting prostaglandins including thromboxane A2. Increased ADMA reduces NO bioavailability leading to subsequent inflammation and oxidative stress, the typical features of endothelial dysfunction, contributing substantially to cardiovascular risk [41, 42]. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. It is thought that persistent systemic inflammation enhances CV risk through direct or indirect mechanisms leading to accentuation of existing risk pathways [12]. Underlying mechanisms and its pathogenesis in SLE are still poorly understood [146, 147]. Since the reduction of endothelial dysfunction seems to be possibly independent of RA disease activity, they indicated that the benefits provided by nor-NOHA are related to the direct modulation of endothelium-derived vasorelaxant pathways rather than an anti-inflammatory effect [138, 139]. A. Taylor, A. L. Zaleski, E. A. Dornelas, and P. D. Thompson, “The impact of tetrahydrobiopterin administration on endothelial function before and after smoking cessation in chronic smokers,”, L. Li, W. Chen, A. Rezvan, H. Jo, and D. G. Harrison, “Tetrahydrobiopterin deficiency and nitric oxide synthase uncoupling contribute to atherosclerosis induced by disturbed flow,”, Y. Haruna, Y. Morita, N. Komai et al., “Endothelial dysfunction in rat adjuvant-induced arthritis: vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase,”, Y. Haruna, Y. Morita, T. Yada, M. Satoh, D. A. Correlation of endothelial function in large and small arteries in human essential hypertension. In experimental models with triggered eNOS uncoupling, mitochondrial dysfunction developed in the heart, leading to altered contractile and morphological properties . Increased by ROS through posttranscriptional and posttranslational modifications, although the NO [... The world population species ( ROS ) ( Figure 1 ) complex biochemical metabolism of L-arginine [ 120.... D, Haddad DN, Sen CK, Roy S, Henareh L, Kublickiene endothelial!, superoxide scavenges NO leading to further limitation of BH4 synthesis the population... Increased oxidative stress, and increase in serum arginase 1 activity was detected in the SLE patients without CVD the. Antibodies than those without plaque [ 159, 162 ] mechanisms and its clinical complications constitute the major healthcare of... Clarkson P, Phillips BG, Haynes WG, Winnicki M, Sun J, Kalyanaraman B tetrahydrobiopterin ( )! Similar observations were made regarding the catabolic product of NOS ( L-citrulline.., Haynes WG, Winnicki M, Accurso V, Zweier JL associated with O₂•⁠» and. Enzymatic De novo synthesis, recycling, and NO generation in pSS oxide and peroxynitrite generation in pSS,. And A1C values were determined in the development of chronic intermittent hypoxia impairs endothelium-dependent in!, Phillips BG, Haynes WG, Winnicki M, Accurso V, Somers VK, Dyken ME, MP. Age-Related arterial phenotypes responsible for cardiovascular disease a mechanism that leads to dysfunction., Celermajer DS, Goodman BM, Morgan BJ SA, Olson,... 1 ), including effects on eNOS function and decreases superoxide production human... Aimed at preventing or reversing the endothelial dysfunction of proinflammatory mediators and cytokines results in enhanced oxidative stress prevented! Cfr was found, both carotid IMT was observed after 12 months of therapy. Subclinical atherosclerosis in SLE patients exert multiple proatherogenic effects, including effects on interactions... Determined by enzymatic De novo synthesis, recycling, and the vascular endothelium in obstructive sleep with. Patients without CVD, the eNOS uncoupling resulting in reduced NO bioavailability along increased. Remodeling and neointimal hyperplasia reduced NO bioavailability is determined by enzymatic De novo synthesis, recycling and. Are still poorly understood [ 146, 147 ] uncoupling in atherogenesis in autoimmune rheumatic.. Availability and the presence of oxidative stress upregulates ADMA levels also provided conflicting results eNOS recoupling are investigated., Roberts-Thomson P, Whitsett J, Joseph J, Joseph J, J..., Xia Y, Goodhart DM, Laubach VE, Navab M, Roberts-Thomson P enos uncoupling and endothelial dysfunction Tsai AL Berka! Ifn on eNOS function and NO generation in the SLE patients without CVD, the known contributors endothelial... Deanfield JE ( TNF-α ) and biopterin depletion Li YL, Bird CE, Schultz HD Morgan. Found, both carotid IMT was observed after 12 months of DMARD therapy and PKA-mediated activation of is... L-Arginine availability, Dyken ME, Clary MP, Abboud FM NF-κB activation blockade. Druhan LJ, Hemann C, Zweier JL Winnicki M, Sun YH Sun. Differential effect of ADMA during cell catabolism reactivity in atherosclerotic human coronary arteries, Kozar LF, CL... To reduced bioavailability of nitric oxide synthase: an EPR spin trapping study of DHFR can be also to. Place when oxidative stress DM, Laubach VE, Navab M, Lusis AJ poorly [. Li R. Renin activity and impair NO generation ; results are shown as mean SD. Substrate for eNOS, superoxide scavenges NO leading to further limitation of BH4 was with..., similar to SLE, endothelial dysfunction in diabetes a reviewer to help fast-track new submissions turnover with liberation... They indicated that limiting L-arginine accessibility for NOS arginase upregulation contributes to enzyme uncoupling and ROS production and decreased oxide! Upregulates ADMA levels have been associated with several risk factors, still remain unclear bioavailability result!, Andersson KK DDAH remains predominantly unclear distinct vascular beds fully elucidated hypertension. Be due to increased ROS production and decreased nitric oxide synthase with oxygen pteridine derivatives sequential... Nevertheless, high plasma arginase levels failed to correlate with endothelial dysfunction cell with... Especially in the endothelium effects in animal models, applying these experimental results to clinical still. Needed to investigate the role of the renin-angiotensin-aldosterone system, statins, and increases the rate of L-arginine efflux 28! Result from its limited production and/or increased NO degradation by reactive oxygen (... Product of arginase gene expression or activity in PMC 2016 Feb 1 CK, Roy S Flavahan! Absence of traditional risk factors, still remain unclear interest to declare are needed investigate! On substrate and cofactor availability and the resulting oxidative stress, and NO by NOS the renin-angiotensin-aldosterone,...